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Pre-renal acute kidney injury (AKI) is assumed to represent a
physiological response to underperfusion. Its diagnosis is
retrospective after a transient rise in plasma creatinine,
usually associated with evidence of altered tubular transport,
particularly that of sodium. In order to test whether pre-renal
AKI is reversible because injury is less severe than that of
sustained AKI, we measured urinary biomarkers of injury
(cystatin C, neutrophil gelatinase-associated lipocalin (NGAL),
c-glutamyl transpeptidase, IL-18, and kidney injury molecule-
1 (KIM-1)) at 0, 12, and 24h following ICU admission. A total
of 529 patients were stratified into groups having no AKI, AKI
with recovery by 24h, recovery by 48h, or the composite of
AKI greater than 48h or dialysis. Pre-renal AKI was identified
in 61 patients as acute injury with recovery within 48h and a
fractional sodium excretion o1%. Biomarker concentrations
significantly and progressively increased with the duration of
AKI. After restricting the AKI recovery within the 48h cohort
to pre-renal AKI, this increase remained significant. The
median concentration of KIM-1, cystatin C, and IL-18 were
significantly greater in pre-renal AKI compared with no-AKI,
while NGAL and c-glutamyl transpeptidase concentrations
were not significant. The median concentration of at least
one biomarker was increased in all but three patients with
pre-renal AKI. Thus, the reason why some but not all
biomarkers were increased requires further study. The results
suggest that pre-renal AKI represents a milder form of injury.
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The concept of ‘pre-renal azotaemia’ is ingrained into the
clinical practice of nephrology.
1 However, the distinction
between pre-renal acute kidney injury (AKI) when used to
classify a group of causes of AKI leading to renal under-
perfusion and pre-renal AKI as a distinct and uniquely
reversible functional type of AKI, rather than AKI due to
parenchymal injury, has often been a source of confusion and
controversy.
1,2 The distinction is potentially important because
it is argued that correction of ‘pre-renal factors’ causing renal
underperfusion may reverse pre-renal AKI, whereas neglecting
these causes AKI to become irreversible. To some, the
diagnosis automatically implies a need for intravenous ﬂuids,
although the cause may be right heart failure or cirrhosis. To
others, the ‘pre-renal’state is not of particular concern, and yet
there is evidence that, even if AKI is reversed, there remains an
increased potential for a range of adverse events including
renal toxicity, volume overload, acid–base and electrolyte
imbalance, abnormal drug elimination, and mortality, parti-
cularly on the background of chronic kidney disease.
3,4 Further
confusion arises from the name, ‘acute tubular necrosis’, being
used to describe ‘established’ pre-renal AKI, implying severe
structural injury, despite a lack of obvious necrosis in most
human biopsies.
Reversal of AKI in less than 24–72h after ﬂuid replacement
is the most common deﬁnition of pre-renal AKI.
5–10 From a
clinical perspective, where the aim is to triage patients as
soon as possible, waiting for reversal delays both diagnosis
and appropriate intervention in those patients who
require more than rehydration to beyond the treatment
window of all potential renoprotective pharmaceutical
therapies.
11 We require clear criteria for the prospective
diagnosis of AKI, rather than diagnosis by exclusion.
Although reversibility could reﬂect structural integrity,
1,10
there is actually little evidence for or against renal structural
integrity in pre-renal AKI.
2,5,12 A low fractional excretion of
sodium (FENa) and/or urea (FEurea)
9,13 are often used to
deﬁne pre-renal AKI, although diuretics and sepsis make
interpretation of the FENa difﬁcult
2,14 and aging and sepsis
alter FEurea.
14,15
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patients classiﬁed as having pre-renal AKI would suggest that
pre-renal AKI is simply part of the continuum of AKI. In that
case, reversibility might be explained simply by less severe
injury. We examined this by prospectively comparing urinary
biomarkers of AKI reported to differentiate pre-renal and
established AKI,
8,16–18 interleukin-18 (IL-18), neutrophil
gelatinase-associated lipocalin (NGAL), kidney injury mole-
cule-1 (KIM-1), cystatin C, and g-glutamyl transpeptidase
(GGT), in a cohort of critically ill patients.
RESULTS
Of 528 patients enrolled in the study, 489 patients had
consecutive plasma creatinine measurements (Figure 1). In
all, 204 patients satisﬁed the Acute Kidney Injury Network
plasma creatinine deﬁnition of AKI, whereas the remaining
patients were classiﬁed as no-AKI (n¼285). Ninety patients
had transient AKI (TAKI), deﬁned as reversal within 48h.
Sixty-one TAKI patients had FENao1 and were therefore
classiﬁed as pre-renal AKI. Among those not classiﬁed, 23
died before 48h and 16 had insufﬁcient measurements for
classiﬁcation. Clinical characteristics of the cohort as a whole
have been given in detail elsewhere.
19,20 Brieﬂy, patients were
61±17 years old, 40.3% women, 61.5% with FENao1%,
18.8% with preexisting CKD, 90.2% on mechanical ventila-
tion, 19.4% with sepsis, and 19% followed cardiac surgery.
Pre-renal AKI and AKI-48 patients had progressively more
severe illness, more CKD, and higher median baseline
creatinine values than no-AKI patients (Table 1).
All biomarker concentrations increased progressively with
increasing duration of AKI (analysis of variance, ANOVA,
Po0.001, Figure 2). After restricting the TAKI cohort to
patients with FENao1% (pre-renal AKI), this increase
remained (ANOVA, Po0.001 for cystatin C (CysC), NGAL,
KIM-1, IL-18, and Po0.01 for GGT following adjustment for
covariates, Figure 3). At least one biomarker concentration
was increased in all but three patients with pre-renal AKI (see
below). All biomarkers had greater median concentrations in
pre-renal AKI than in no-AKI, and the KIM-1, CysC, and IL-
18 distributions differed from no-AKI in post-hoc analysis
(Mann–Whitney, Po0.05, Table 2).
Pre-renal AKI and AKI-48 patients had progressively
greater proportions of biomarkers above the median of the
no-AKI group (Figure 4). We analyzed the pre-renal AKI and
AKI-48 patients with no evidence of increased biomarker
concentrations (no biomarker above the median of the no-AKI
group) for factors such as reduced baseline estimated
glomerular ﬁltration rate (GFR) and very short or very long
insult to admission time intervals, as these factors could have
caused misclassiﬁcation as AKI or reduced biomarker
performance.
20 There were only three patients with biomarker
concentrations less than the median biomarker concentration
for no-AKI, and these were in the pre-renal AKI group. In each
of these cases, the diagnosis of AKI was based on a post-entry
trough creatinine concentration between 50 and 60mmol/l and
a relatively low maximum creatinine concentration (80 or
90mmol/l). None were oliguric. The clinical diagnosis was
burns, trauma, or sub-arachnoid hemorrhage, and the time
from onset to ﬁrst creatinine measurement ranged from 7 to
17h. A further ﬁve pre-renal AKI patients had only one
biomarker greater than the median of the no-AKI group. The
putative insult was more than 24h before the ﬁrst measure-
ment in two patients. The short time course of GGT may
explain why some biomarker concentrations were not
increased.
20 Two of the remaining ﬁve patients had underlying
CKD; KIM-1 was increased in one and IL-18 in the other. The
ﬁfth and ﬁnal patient samples were obtained 4h after
abdominal surgery, when only GGT was increased, which is
consistent with the short time course of this biomarker.
20
Urinary biomarker concentrations were compared with
the absolute FENa. Within the total cohort only GGT was
correlated, although poorly so (Spearman’s rho¼0.13,
P¼0.003). Within the cohort with FENaX1, only CysC
and NGAL concentrations were correlated (also poorly) with
increasing FENa. For CysC, Spearman’s rho was 0.21
(P¼0.0062); for NGAL rho was 0.17 (P¼0.023). No
corresponding correlations were seen with the FEUrea data
(note this is a smaller data set).
No patient for whom AKI was transient (o48h) needed
dialysis, but 15.8% (n¼19) of patients in AKI-48 group
required renal replacement therapy, Table 3. Mortality
increased with increasing duration of AKI (no-AKI, 9.1%
(n¼26); TAKI, 12.2% (11); AKI-48, 18.4% (21)), w
2 test for
trend, Po0.01) and length of intensive care unit (ICU) stay
was longer (Po0.0001).
Enrolled patients
n=528
Insufficient measurements
n=16
Analyzed patients
n=489
AKI
n=204
Control
n=285
Transient AKI
n=90
AKI-48
n=114
AKI 24–48
n=26
AKI-24
n=64
FENa (n) 277 64 26
Pre-renal AKI (n=61)
(FENa<1)
113
Died before 48h
n=23
Figure 1|Patient flow and numbers (n). Fractional excretion of
sodium (FENa; n): patients for whom a fractional excretion of
sodium was measured. Acute kidney injury (AKI) 24: recovery
within 24h. AKI 24–48: recovery 24–48h. AKI-48: no recovery
within 48h or renal replacement therapy. Pre-renal AKI: transient
AKI and FENao1.
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The possibility that sepsis confounded the FENa measure-
ment
2,15 was examined by analyzing the subgroup without
sepsis (n¼394). All biomarkers increased with increasing
duration of AKI (Supplementary Figure 1 online), and GGT
was increased in pre-renal AKI-FENa compared with no-AKI
(Po0.05, Supplementary Tables 1 and 2 online).
As FEureao35 is as an alternative to FENao1 for deﬁning
pre-renal AKI, FEurea was measured in 313 patients in one of
the two centers. Twenty-nine patients had TAKI plus
FEureao35. Urinary CysC, NGAL, and IL-18 were elevated
in this group compared with the no-AKI group (Supple-
mentary Table 3 online).
DISCUSSION
In this prospective study of critically ill ICU patients, we
observed that urinary biomarker concentrations increased
with increasing duration of AKI, and for urinary CysC, IL-18,
and KIM-1 these were signiﬁcantly increased in pre-renal
AKI compared with patients with no-AKI.
In experimental nephrotoxic injury, the concentrations of
renal injury biomarkers increase in proportion to the degree
of structural renal injury.
21 However, no renal biopsy studies
in humans have been conducted to ascertain the exact
relationship between structural renal injury and the urinary
biomarkers measured in this study. Many studies have,
nevertheless, demonstrated a correlation between urinary
biomarker concentration and functional severity,
22,23 and
several have demonstrated that values above a given cutoff
predict hard outcomes including dialysis and death.
24,25
Although it remains an assumption that increased urinary
biomarker concentrations represent increased structural
injury, the results presented here demonstrate that both
transient (reversible) and prolonged (perhaps irreversible)
increases in plasma creatinine were associated with increased
urinary biomarker concentrations and that these increased
with duration of AKI. The presence of retained tubular
function demonstrated by a normal FENa (o1%) did not
modify this outcome.
These data support the hypothesis that pre-renal AKI and
what might be called ‘established’ AKI represent a continuum
of injury. The extent of increase in urinary biomarker
concentration in TAKI and TAKI plus low FENa was
signiﬁcantly less than that seen with AKI lasting longer than
48h. This suggests that reversibility attributed to ‘functional’
rather than ‘structural’ injury may simply reﬂect a lesser
degree of structural injury, which is nevertheless present at
both ends of the AKI continuum. This is consistent with the
patchy (focal) nature of histological change observed in those
rare cases of clinical AKI where renal biopsy is available.
26 By
analogy to non-ST segment elevation myocardial infarction,
we speculate that injury to a limited number of nephrons will
inevitably produce detectable increases in urinary biomarker
concentration, but compensation by residual normally
Table 1|Clinical characteristics and outcomes
Demographic No-AKI Pre-renal AKI-48 P
Age, mean (s.d.), years 60 (17) 58 (17) 65 (16) 0.011
Female, % (no.) 43.9 (125) 37.7 (23) 30.7 (35) 0.061
Weight, mean (s.d.), kg 78 (19) 83 (19) 85 (21) 0.0028
APACHE II, mean (s.d.) 16 (5) 18 (6) 21 (6) o0.0001
SOFA, mean (s.d.) 5.4 (2.4) 6.7 (2.7) 8.1 (2.9) o0.0001
FENa, median (IQR), % 0.68 (0.28–1.7) 0.25 (0.13–0.50) 0.76 (0.34–1.7)
FEurea, median (IQR), %
a 45 (33–60) 32 (17–42) 29 (18–40) o0.0001
FENao1, % (no.) 58.6 (167) 100 (61) 58.8 (67)
FEurea o35, % (no.)
a 16.1 (46) 42.6 (26) 43.9 (50) o0.0001
Baseline plasma creatinine, median (IQR), mg/dl 0.79 (0.68–1.0) 0.83 (0.68–1.0) 0.99 (0.79–1.2) o0.0001
AKI on admission — 70.5 (43) 70.2 (80)
CKD on admission, % (no.), baseline eGFRo60ml/min 17.2 (49) 13.1 (8) 28.1 (32) 0.026
Mechanical ventilation, % (no.) 90.9 (259) 82 (50) 91.2 (104) 0.79
Hypotension, % (no.) 51 (144) 51 (31) 61 (70) 0.062
Diagnostic class
Abdominal aortic aneurysm rupture and repair 1.8 (5) 3.3 (2) 11 (13)
Abdominal surgery or inflammation 12 (33) 12 (7) 8.8 (10)
Burns 0.35 (1) 3.3 (2) 0
Cardiac arrest or failure 11 (31) 15 (9) 6.1 (7)
Cardiac surgery 20 (57) 8.2 (5) 20 (23)
Collapse, cause unknown 0.35 (1) 3.3 (2) 0
Neurological surgery, injury, seizure, or hemorrhage 15.8 (9) 15 (9) 4.4 (5)
Other 0.7 (2) 0 0
Pulmonary or thoracic surgery or failure 13 (37) 9.8 (6) 17 (19)
Sepsis 15 (43) 26 (16) 28 (32)
Trauma 11 (30) 4.9 (3) 4.4 (5)
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; FENa, fractional excretion of sodium; FEurea, fractional
excretion of urea; IQR, interquartile range.
aAvailable from one center only (no-AKI, n=162; pre-renal AKI, n=43; AKI-48, n=77).
P-values are one-way ANOVA or w
2 test for trend.
1256 Kidney International (2012) 81, 1254–1262
original article M Nejat et al.: Some biomarkers are increased in pre-renal acute injury10
* ***
***
***
***
*** **
#
**
##
#
Ø
ØØ
1
0.1
C
y
s
t
a
t
i
n
 
C
 
i
n
d
e
x
N
G
A
L
 
i
n
d
e
x
G
G
T
 
i
n
d
e
x
I
L
-
1
8
 
i
n
d
e
x
K
I
M
-
1
 
i
n
d
e
x
0.01
0.001
1000.0
100.0
10.0
1.0
1
10
100
1
0.01
0.0001
1000
No-AKI AKI-24 AKI 24–48 AKI-48
10
100
100
Figure 2|Effect of duration of acute kidney injury (AKI) on
urinary biomarker concentration. Cystatin C (CysC) (a),
neutrophil gelatinase-associated lipocalin (NGAL) (b), g-glutamyl
transpeptidase (GGT) (c), interleukin (IL)-18 (d), and kidney injury
molecule (KIM)-1 (e). All biomarkers, Po0.001 (analysis of
variance). Post-hoc difference from no-AKI*, AKI 24–48, or
AKI-48 from AKI-24
#, AKI 24–48 vs. AKI-48
+ (*
,#,+Po0.05,
**
,##,++Po0.01, ***Po0.001). Whiskers 10th–90th percentile.
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Figure 3|Effect of pre-renal acute kidney injury (AKI) and
AKI-48 on urinary biomarker concentration. Cystatin C (CysC) (a),
neutrophil gelatinase-associated lipocalin (NGAL) (b), g-glutamyl trans-
peptidase (GGT) (c), interleukin (IL)-18 (d), and kidney injury molecule
(KIM)-1 (e). All biomarkers, Po0.001 (analysis of variance). Post-hoc least
significant difference from no-AKI*, from pre-renal AKI
# (*Po0.05,
##Po0.01, ***
,###Po0.001). Whiskers 10th–90th percentile.
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although some distinction between glomerular and tubular
function also needs to be drawn, as discussed below. Clearly,
further studies are required to validate these suggestions.
The overall lack of correlation between FENa and
biomarker concentration for all biomarkers except GGT
(where there was a relatively poor correlation) suggests that
these biomarkers are not surrogate measures of sodium
handling. However, when sodium absorption was reduced
(FENa 41) there was a modest correlation between FENa and
CysC and NGAL. We suggest two possible explanations: (i)
CysC and NGAL appear to have longer time courses than the
other biomarkers,
20 which may have allowed a linkage to FENa
to be more obvious than with shorter time-course biomarkers;
(ii) of the ﬁve biomarkers examined, only CysC and NGAL are
ﬁltered by the glomerulus and reabsorbed in the proximal
tubules, suggesting, although different transport mechanisms
are involved, that impaired proximal tubular transport
functions may link increases in the urinary concentrations
of these biomarkers to FENa, analogous to the effect of
albuminuria and proteinuria on the reabsorption of these
biomarkers.
27
All patients were maximally hydrated on admission to ICU
and received inotrope support as required. Fluid resuscitation
is an important component in the assessment and treatment
of critically ill patients in the ICU and often begins in the
emergency department, where high ﬂuid loading is a normal
practice. The results suggest that demonstration of retained
tubular function or waiting for a decrease in creatinine to
diagnose pre-renal AKI is unnecessary and that the severity of
renal injury will deﬁne the response to ﬂuid loading. Thus, a
separation of pre-renal ‘azotemia’ from established AKI is
unnecessary and is not useful in clinical practice, as it may
delay additional investigations or intervention. As pre-renal
AKI is associated with tubular injury, it is the degree of
tubular injury reﬂected by the extent of increase in urinary
biomarker concentration that is important. The extent of
urinary biomarker increase is inversely related to the extent
to which tubular function is retained, as reﬂected in the
stepwise increase in early biomarker concentrations when
progressing from normal to pre-renal to established AKI
observed in this study.
Although other studies have not addressed this question
directly, their results are consistent with these conclusions. In
the emergency department study of Nickolas et al,
8 30 of 635
patients were classiﬁed as having AKI according to the RIFLE
criteria, and 88 others who met the RIFLE criteria were
classiﬁed as pre-renal azotemia because FENa was o1% on
presentation or they recovered normal plasma creatinine
concentrations within 3 days. The urinary NGAL/urinary
creatinine concentration was signiﬁcantly higher in patients
with AKI than those who recovered from AKI within 3 days
(416±387 vs. 30.1±92.0), Po0.001; mean±s.d., mg/g creatinine).
Similarly, urinary IL-18/creatinine (mean±s.e., pg/mg) was
greater in patients with acute tubular necrosis (814±151,
n¼14) compared with patients classiﬁed as having pre-
renal azotaemia (155±68, n¼8), or healthy controls (23±9,
n¼11). In that study, patients with acute tubular necrosis or
pre-renal azotemia were adjudicated by the renal consultant
based on plasma creatinine changes in respond to ﬂuid
therapy, urine microscopy, and FENao1%.
28,29
Recently, Singer et al.
30 investigated whether urinary NGAL
could be used to distinguish between pre-renal and intrinsic
AKI in a cohort of 145 patients with AKI according to the
RIFLE criteria on the day of enrolment. Patients were
classiﬁed as pre-renal AKI (n¼33) when plasma creatinine
returned to baseline within 3 days and the cause of increase in
creatinine was determined to be factors that compromised
renal perfusion, and there was no exposure to nephrotoxins.
Patients were classiﬁed as intrinsic AKIwhen potential tubular
necrosis–inducing events could be identiﬁed and there was no
response to ﬂuid resuscitation and/or hemodynamic stabiliza-
tion (n¼75). A large number of patients (n¼38) could not
be classiﬁed. Urinary NGAL concentrations were greater in
Table 2|Urinary biomarker concentrations
a
Biomarker No-AKI (n=285)
b
Pre-renal AKI
(n=61)
c
Pre-renal AKI
vs. no-AKI
P-value AKI 48 (n=114)
d
AKI 48 vs. no-AKI
P-value
AKI 48 vs. pre-
renal AKI
P-value
Test for trend
P-value (ANOVA)
e
CysC, median (IQR)
mg/mmolCr
0.026 (0.010–0.12) 0.054 (0.017–0.53) 0.017 0.21 (0.05–1.9) o0.001 0.0097 o0.001
NGAL, median (IQR)
mg/mmolCr
7.7 (3.3–35) 14 (6.5–56) 0.052 44 (16–345) o0.001 o0.001 o0.001
GGT, median (IQR)
U/mmolCr
13 (8.2–24) 17 (9.6–33) 0.097 18.5 (9.9–45) o0.001 0.25 o0.01
IL-18, median (IQR)
ng/mmolCr
1.6 (0.001–25) 10.9 (0.001–66) 0.017 22 (0.16–137) o0.001 0.053 o0.001
KIM-1, median (IQR)
mg/mmolCr
170 (69–445) 297 (121–549) 0.028 376 (169–943) o0.001 0.034 o0.001
Abbreviations: AKI, acute kidney injury; CysC, cystatin C; GGT, g-glutamyl transpeptidase; IL, interleukin; IQR, interquartile range; KIM, kidney injury molecule; NGAL, neutrophil
gelatinase-associated lipocalin.
aBiomarker concentrations shown are the median (IQR) of the maximum concentration indexed to creatinine within 24h of admission.
bFor all biomarkers except NGAL: n=280.
cFor all biomarkers except NGAL: n=57.
dFor all biomarkers except NGAL: n=103.
eAfter adjustment for age, sex, APACHE II score, and estimated baseline glomerular filtration rate and sepsis.
Significance is vs. no-AKI in each case.
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greater in those who went on to increase their RIFLE severity
class or to die. FENa did not discriminate between pre-renal
and intrinsic AKI. Unfortunately, this study lacked a cohort of
patients without AKI, which makes comparison with our
study difﬁcult, and the large number of unclassiﬁable patients
calls the conclusions into some doubt as well. The approach of
retrospectively determining the likely cause of increased
creatinine and waiting to see which patients creatinine levels
returned to normal may have resulted in choosing two
cohorts with differing severity of parenchymal injury rather
than a separate cohort with only a physiological response.
Thus, although recent studies could distinguish biomarker
cutoffs that deﬁned ‘established’ from pre-renal AKI, they
nevertheless documented evidence of structural injury in the
pre-renal group. Similarly, evidence of structural injury was
also observed in the earliest studies of reversible accumula-
tion of nitrogenous wastes in healthy volunteers. In the study
of Coller and Maddock,
29 proteinuria and casts appeared in
the urine after 2 days, and hematuria was also present after
3 days of water deprivation. These features resolved along
with nitrogen retention when access to water was permitted,
although proteinuria was the slowest to clear.
In this study, mortality in patients with TAKI was greater
than in no-AKI patients (12% vs. 9%, Po0.01). This is
consistent with the larger observational study of Uchino
et al.
10 of 20,126 hospital patients, where patients who
recovered within 3 days had a greater than twofold (odds
ratio: 2.26), and patients classiﬁed as acute tubular necrosis
(no renal recovery within 3 days or received dialysis) a sixfold
(odds ratio: 6.07), increase in hospital mortality compared
with patients without AKI. Similarly, the study of Coca et al.
31
of 35,302 diabetic veterans showed that long-term mortality
increased with duration of AKI after noncardiac surgery.
It has previously been argued that the concept of pre-renal
AKI is ﬂawed in AKI associated with sepsis.
2 Although renal
underperfusion leading to necrosis does not appear to be the
dominant injury paradigm in sepsis, our data additionally
demonstrate that structural injury has occurred in these patients,
as TAKI was associated with increased urinary biomarker
concentrations in both patients with sepsis and without.
If pre-renal AKI simply represents the milder end of the
spectrum of AKI with preservation of sodium handling, what
use, then, are traditional markers of tubular function? We
suggest that previous studies are consistent with the notion
that tubular function is better preserved with briefer or less
severe renal injury. For example, Pepin et al.
9 showed that, in
patients not receiving diuretics, FENa was better than FEurea
in distinguishing persistent AKI from transient AKI (deﬁned
as recovery from a X30% increase in plasma creatinine
within 1 week; area under the curve, 0.83±0.07 vs.
0.56±0.11, respectively). In the same study, the FENa was
three to four times higher in patients with persistent AKI
compared with transient AKI, regardless of whether patients
were receiving diuretics. Nevertheless, this combination of
apparently preserved tubular function and an increased
creatinine (indicating a reduction in GFR) coupled with an
increase in injury biomarkers suggests that standard markers
of tubular function are less sensitive to renal injury than
Table 3|Outcomes according to AKI status
Outcome
No-AKI
(n=285)
Pre-renal AKI
(n=61)
AKI 48
(n=114)
Test for
trend
P-value
RRT, % (n) 0 0 15.8 (19) o0.0001
Death in 30 days,
%( n)
9.1 (26) 9.8 (6) 18.4 (21) 0.012
Length of ICU
stay (h)
68 (41–160) 103 (50–196) 141 (66–270) o0.0001
Abbreviations: AKI, acute kidney injury; ICU, intensive care unit; RRT, renal
replacement therapy.
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Figure 4|Proportion of patients with n biomarkers above the
median or upper quartile of the no-acute kidney injury (AKI)
group. (a) No-AKI is normally distributed. A greater proportion of
patients have multiple biomarkers elevated in the pre-renal AKI
and AKI groups. (b) Progressively fewer biomarkers have no
biomarker above the upper quartile of the no-AKI group, whereas
progressively more have 3, 4, or 5 biomarkers above the upper
quartile of the no-AKI group.
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Consistent with the concept that injury is focal in human
AKI, as already highlighted above, this further suggests that
renal autoregulation of GFR is more sensitive to injury than
markers of tubular transport function such as FENa. Tubular
transport mechanisms are either more resilient or compen-
sated for by normal nephrons. A consistent paradigm is that
less severe ‘pre-renal mechanisms’,
32 which reduce nephron
plasma ﬂow, the glomerular hydraulic pressure gradient
ultraﬁltration coefﬁcient, or the oncotic pressure gradient
resulting in reduced single-nephron GFR, result in tubular
injury to some but not all nephrons. This combination will
result in apparent preservation of ‘overall’ tests of tubular
transport function, such as FENa, but with injury revealed by
increasing urinary biomarker concentrations.
A recent retrospective analysis by Haase et al.
33 of cohort
studies of patients with cardio-renal disease demonstrated that
an increase in plasma NGAL without an increase in plasma
creatinine nevertheless predicted an increase in dialysis and
mortality. Similarly, we observed in the no-AKI group that the
addition of urinary NGAL increased the area under the curve
(from 0.61 (95% conﬁdence interval: 0.49–0.73) to 0.66
(0.54–0.78), Po0.05) for predicting death within 30 days in
a logistic regression model of variables, which were associated
with mortality under univariate analysis (age, weight,
APACHE II score). This suggests that injury biomarkers have
an important role in the classiﬁcation and management of AKI
in addition to stages deﬁned by creatinine.
Only three patients matching our deﬁnition of pre-renal
AKI appeared to have no increase in urinary biomarkers in
this study. Although the formulaic classiﬁcation (compared
with a clinical adjudication) may have been responsible for
classifying these as pre-renal AKI instead of as ‘no-AKI’, we
cannot rule out the possibility that they were true noninjury
pre-renal AKI.
Our analysis, as with all biomarker analyses of urinary AKI
biomarkers, treats the biomarkers as continuous variables.
However, the pathophysiology suggests that some of these
biomarkers are categorical. This may account for skewed
concentration distributions and complicates the statistical
analysis. For example, IL18, a pro-inﬂammatory cytokine, is
upregulated in proximal epithelial cells and recruited macro-
phages during ischaemia/reperfusion injury. In our study, 55%
of patients on entry to ICU had an IL18 concentration below
the level of detection, leading to a highly skewed distribution.
For this reason, we analyzed the results nonparametrically
(Mann–Whitney U test comparison between each group), as
well as parametrically following log transform (ANOVA with
least signiﬁcant difference post-hoc test).
Although patients were vigorously hydrated in accordance
with ICU practice, our study was limited by a lack of ﬂuid
balance data to rule out volume depletion or objectify the
response to deliberate ﬂuid loading. Similarly, we lack data
on diuretic use. By normalizing the biomarkers to urinary
creatinine, we account, at least in part, for any potential
differences in ﬂuid loading.
34 Although the largest study of its
kind, the study remains limited by size; nearly 8% of patients
were excluded because of insufﬁcient follow-up plasma
creatinine measurements or death before 48h after admis-
sion. NGAL results were unavailable in another 4% of
patients. Consequently, the modest number of patients in
each group after stratiﬁcation for duration and FENa means
that the conclusions require validation in larger studies.
In summary, in critically ill patients, urinary biomarkers of
injury increase in concentration with duration of AKI
regardless of whether there is preservation of tubular function,
as typiﬁed by a low FENa. This suggests that pre-renal AKI is
simply a mild form of structural AKI rather than a unique
functional form of AKI. Early return of renal function, as
demonstrated by a decrease in creatinine, probably represents
recovery, not reversibility, of a unique ‘physiological’ increase
in serum creatinine. Although it remains theoretically possible
that GFR may decrease in the absence of renal tubular injury,
until there are studies demonstrating that urinary biomarkers
of renal injury are absent in such cases, we suggest that the
term ‘pre-renal mechanisms’ be used for classifying etiology
but not type of AKI. Perhaps in the future AKI may be
categorized according to extent of injury (biomarker con-
centration), extent and duration of glomerular functional
change, and preservation or otherwise of sodium reabsorption
or other tubular functions.
MATERIALS AND METHODS
The prospective observational study of FENa and FEurea and urinary
biomarkers of AKI was a planned component of the combined
observational and interventional study, EARLYARF, in two large
general ICUs in two regional centers.
19,20 The study was approved by
the Multiregional Ethics Committee of New Zealand (MEC/
050020029) and registered under the Australian New Zealand
Clinical Trials Registry (ACTRN012606000032550, http://www.actr.
org.au). Inclusion/exclusion criteria, consent procedures, sample
collection, and details of analysis for urinary GGT, CysC, IL-18,
KIM-1, NGAL, and creatinine have been detailed elsewhere.
19,20
Brieﬂy, eligible patients were all adults expected to remain in the ICU
for 424h, survive 472h, and had not experienced a threefold or
greater rise in creatinine on entry, were not anuric, on renal
replacement therapy or assessed to need renal replacement therapy
within 48h, and did not have hematuria, rhabdomyolosis,
myoglobinuria, or polycythemia, and were not receiving chemother-
apy. Patients were randomized to a placebo-controlled trial of high-
dose erythropoietin. As erythropoietin had no effect on outcome,
the present analysis combines patients in both observation and
intervention arms.
19 Investigators blinded to patients’ clinical
characteristics performed all assays. Biomarker concentrations were
indexed to urinary creatinine concentration in the same sample.
Urine and plasma sodium and urea were measured on entry to
ICU. Other biomarkers were measured on entry, and at 12 and 24h
post entry. Plasma creatinine was measured daily for 7 days. Urine
samples were stored at  801C until batch analysis for CysC, KIM-1,
IL-18, or NGAL. The maximum indexed urinary biomarker
concentration within 24h was used for this analysis. The FENa
was calculated using the following formula: FENa¼(plasma
creatinine urinary Na)/(plasma Na urinary creatinine). Baseline
creatinine was determined as previously described.
19 Brieﬂy, 51% of
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remaining patients, the lowest of the on-admission, ﬁnal ICU, or
follow-up creatinine was used. A similar approach in this cohort has
been shown to be more accurate than using the Modiﬁcation of Diet
in Renal Disease equation with the same assumed GFR to back-
calculate a baseline creatinine.
35
AKI was deﬁned using the Acute Kidney Injury Network criteria as
an absolute increase in plasma creatinine above baseline of at least
0.3mg/dl (26.4mmol/l) or a percentage increase of at least 50%.
36
AKI status was determined at admission to the ICU, and 24 and 48h
later. Patients were stratiﬁed according to duration of AKI: (i)
recovery within 24h (AKI-24), (ii) recovery between 24 and 48h
(AKI 24–48), (iii) no recovery within 48h or renal replacement
therapy (AKI-48). TAKI was deﬁned as AKI-24 or AKI 24–48.
Recovery was deﬁned as a reduction of plasma creatinine to
o0.3mg/dl above baseline. Patients with no-AKI within 48h of
entry served as the control group (no-AKI). Pre-renal AKI was
deﬁned as TAKI combined with a low fractional sodium excretion,
FENa, o1%. Covariates were variables with Po0.1 following
univariate analysis for the difference between no-AKI and pre-renal
AKI or AKI-48. Covariates were age, sex, APACHE II score, and
estimated baseline GFR (eGFR: using the Modiﬁcation of Diet in
Renal Disease formula) and sepsis.
Results were expressed as frequencies, mean±s.d., and medians
and interquartile range. Differences between the distributions were
assessed by ANOVA with Least Squares Difference for post-hoc
analysis of the difference between groups, w
2 and Mann–Whitney
U test, and sensitivity analysis. Analysis was performed with SPSS
version 16 (SPSS, Chicago, IL) and GraphPad Prism 5.0a (GraphPad
Software, San Diego, CA).
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